Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
leukocyte interleukin + cyclophosphamide + indomethacin + zinc
- Development stage
- Unknown
- Lead developer
- CEL-SCI
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Peritumoural Injection, Perilymphatic Injection, Intravenous, Oral
01
Overview
Leukocyte interleukin + cyclophosphamide + indomethacin + zinc is a combination immunotherapy regimen primarily investigated as a neoadjuvant treatment for locally advanced, previously untreated squamous cell carcinoma of the head and neck. The combination consists of leukocyte interleukin (LI, branded as Multikine), a defined mixture of 36 pro-inflammatory human cytokines derived from healthy donor blood which stimulate anti-tumor immune responses, combined with cyclophosphamide (immunomodulatory agent and alkylating chemotherapy), indomethacin (NSAID that reduces prostaglandin-mediated immune suppression), and zinc (important for immune function)[3][2][4]. The regimen aims to activate and direct the immune system against tumor cells while modulating the tumor microenvironment and reducing suppressive immune responses. It is administered via local/regional injection (LI) and corresponding oral/IV dosing of the other agents.
- Other names
- leukocyte interleukin with cyclophosphamide, indomethacin, and zincLI plus CIZ
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on leukocyte interleukin + cyclophosphamide + indomethacin + zinc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on leukocyte interleukin + cyclophosphamide + indomethacin + zinc.